SAB Historical Financial Ratios

SABSW Stock

USD 0.11 0.04 26.67%

SAB Biotherapeutics is promptly reporting on over 77 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Book Value Per Share of 7.5, Invested Capital of 0.0, Average Payables of 4.1 M or Stock Based Compensation To Revenue of 1.02 will help investors to properly organize and evaluate SAB Biotherapeutics financial condition quickly.

Quick Ratio Current Ratio

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in SAB Biotherapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

For more information on how to buy SAB Stock please use our How to Invest in SAB Biotherapeutics guide.

About SAB Financial Ratios Analysis

SAB BiotherapeuticsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate SAB Biotherapeutics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on SAB financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across SAB Biotherapeutics history.

SAB Biotherapeutics Financial Ratios Chart

At this time, SAB Biotherapeutics' EV To Free Cash Flow is fairly stable compared to the past year. Net Debt To EBITDA is likely to climb to 1.26 in 2025, whereas Book Value Per Share is likely to drop 7.50 in 2025.

Price To Sales Ratio Days Sales Outstanding Average Payables Payables Turnover

Add Fundamental

Price To Sales Ratio

Price to Sales Ratio is figured by comparing SAB Biotherapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on SAB Biotherapeutics sales, a figure that is much harder to manipulate than other SAB Biotherapeutics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Average Payables

The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.

Payables Turnover

A liquidity ratio that shows how quickly a company pays off its suppliers by dividing total purchases by average accounts payable.

Most ratios from SAB Biotherapeutics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into SAB Biotherapeutics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in SAB Biotherapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

For more information on how to buy SAB Stock please use our How to Invest in SAB Biotherapeutics guide.At this time, SAB Biotherapeutics' EV To Free Cash Flow is fairly stable compared to the past year. Net Debt To EBITDA is likely to climb to 1.26 in 2025, whereas Book Value Per Share is likely to drop 7.50 in 2025.

	2022	2024	2025 (projected)
Graham Number	26.29	38.02	26.62
Receivables Turnover	4.3	3.87	3.16

Graham Number Receivables Turnover

SAB Biotherapeutics fundamentals Correlations

	Price To Sales Ratio	Ptb Ratio	Days Sales Outstanding	Book Value Per Share	Free Cash Flow Yield	Operating Cash Flow Per Share	Average Payables	Capex To Depreciation	Pb Ratio	Ev To Sales	Free Cash Flow Per Share	Roic	Net Income Per Share	Payables Turnover	Capex To Revenue	Cash Per Share	Pocfratio	Interest Coverage	Capex To Operating Cash Flow	Pfcf Ratio	Days Payables Outstanding	Income Quality	Roe	Ev To Operating Cash Flow	Pe Ratio	Return On Tangible Assets
Price To Sales Ratio		-1.0	0.98	-0.94	0.71	0.25	0.71	-0.38	-1.0	1.0	0.83	-0.4	0.51	-0.65	-0.05	-0.88	-1.0	0.6	-0.61	-0.99	0.73	0.85	0.99	-1.0	-1.0	-0.47
Ptb Ratio	-1.0		-0.98	0.94	-0.71	-0.26	-0.71	0.38	1.0	-1.0	-0.83	0.4	-0.51	0.66	0.05	0.88	1.0	-0.6	0.6	0.99	-0.73	-0.85	-0.99	1.0	1.0	0.46
Days Sales Outstanding	0.98	-0.98		-0.93	0.65	0.21	0.74	-0.33	-0.98	0.97	0.79	-0.35	0.56	-0.59	-0.1	-0.93	-0.98	0.6	-0.69	-0.98	0.68	0.89	0.97	-0.98	-0.97	-0.42
Book Value Per Share	-0.94	0.94	-0.93		-0.5	-0.02	-0.58	0.58	0.94	-0.94	-0.69	0.66	-0.29	0.46	0.01	0.89	0.95	-0.33	0.63	0.9	-0.49	-0.79	-0.9	0.95	0.94	0.68
Free Cash Flow Yield	0.71	-0.71	0.65	-0.5		0.84	0.87	0.26	-0.71	0.72	0.95	0.15	0.79	-0.98	0.37	-0.64	-0.68	0.92	0.02	-0.76	0.98	0.38	0.78	-0.69	-0.71	0.19
Operating Cash Flow Per Share	0.25	-0.26	0.21	-0.02	0.84		0.7	0.7	-0.26	0.26	0.74	0.5	0.8	-0.88	0.63	-0.33	-0.22	0.85	0.44	-0.33	0.79	-0.05	0.36	-0.22	-0.25	0.64
Average Payables	0.71	-0.71	0.74	-0.58	0.87	0.7		0.2	-0.71	0.71	0.88	0.06	0.76	-0.87	0.31	-0.81	-0.69	0.83	-0.12	-0.75	0.86	0.42	0.76	-0.69	-0.71	0.11
Capex To Depreciation	-0.38	0.38	-0.33	0.58	0.26	0.7	0.2		0.38	-0.37	0.12	0.9	0.59	-0.29	0.41	0.18	0.4	0.49	0.51	0.29	0.23	-0.36	-0.26	0.4	0.39	0.99
Pb Ratio	-1.0	1.0	-0.98	0.94	-0.71	-0.26	-0.71	0.38		-1.0	-0.83	0.4	-0.51	0.66	0.05	0.88	1.0	-0.6	0.6	0.99	-0.73	-0.85	-0.99	1.0	1.0	0.46
Ev To Sales	1.0	-1.0	0.97	-0.94	0.72	0.26	0.71	-0.37	-1.0		0.83	-0.39	0.52	-0.66	-0.05	-0.88	-1.0	0.61	-0.6	-1.0	0.74	0.85	0.99	-1.0	-1.0	-0.46
Free Cash Flow Per Share	0.83	-0.83	0.79	-0.69	0.95	0.74	0.88	0.12	-0.83	0.83		-0.04	0.8	-0.94	0.4	-0.83	-0.81	0.87	-0.16	-0.87	0.92	0.54	0.88	-0.82	-0.83	0.02
Roic	-0.4	0.4	-0.35	0.66	0.15	0.5	0.06	0.9	0.4	-0.39	-0.04		0.48	-0.12	-0.01	0.35	0.42	0.44	0.32	0.3	0.19	-0.25	-0.28	0.42	0.41	0.94
Net Income Per Share	0.51	-0.51	0.56	-0.29	0.79	0.8	0.76	0.59	-0.51	0.52	0.8	0.48		-0.76	0.31	-0.63	-0.5	0.94	-0.13	-0.59	0.78	0.45	0.62	-0.5	-0.5	0.5
Payables Turnover	-0.65	0.66	-0.59	0.46	-0.98	-0.88	-0.87	-0.29	0.66	-0.66	-0.94	-0.12	-0.76		-0.49	0.63	0.62	-0.88	-0.13	0.7	-0.95	-0.29	-0.72	0.63	0.66	-0.21
Capex To Revenue	-0.05	0.05	-0.1	0.01	0.37	0.63	0.31	0.41	0.05	-0.05	0.4	-0.01	0.31	-0.49		-0.22	0.06	0.23	0.66	0.03	0.22	-0.41	-0.01	0.05	0.05	0.32
Cash Per Share	-0.88	0.88	-0.93	0.89	-0.64	-0.33	-0.81	0.18	0.88	-0.88	-0.83	0.35	-0.63	0.63	-0.22		0.89	-0.58	0.5	0.88	-0.61	-0.72	-0.89	0.88	0.87	0.31
Pocfratio	-1.0	1.0	-0.98	0.95	-0.68	-0.22	-0.69	0.4	1.0	-1.0	-0.81	0.42	-0.5	0.62	0.06	0.89		-0.57	0.63	0.99	-0.7	-0.86	-0.99	1.0	1.0	0.49
Interest Coverage	0.6	-0.6	0.6	-0.33	0.92	0.85	0.83	0.49	-0.6	0.61	0.87	0.44	0.94	-0.88	0.23	-0.58	-0.57		-0.08	-0.68	0.94	0.44	0.7	-0.58	-0.6	0.42
Capex To Operating Cash Flow	-0.61	0.6	-0.69	0.63	0.02	0.44	-0.12	0.51	0.6	-0.6	-0.16	0.32	-0.13	-0.13	0.66	0.5	0.63	-0.08		0.58	-0.06	-0.9	-0.57	0.63	0.6	0.55
Pfcf Ratio	-0.99	0.99	-0.98	0.9	-0.76	-0.33	-0.75	0.29	0.99	-1.0	-0.87	0.3	-0.59	0.7	0.03	0.88	0.99	-0.68	0.58		-0.78	-0.85	-1.0	0.99	0.99	0.37
Days Payables Outstanding	0.73	-0.73	0.68	-0.49	0.98	0.79	0.86	0.23	-0.73	0.74	0.92	0.19	0.78	-0.95	0.22	-0.61	-0.7	0.94	-0.06	-0.78		0.45	0.8	-0.7	-0.73	0.18
Income Quality	0.85	-0.85	0.89	-0.79	0.38	-0.05	0.42	-0.36	-0.85	0.85	0.54	-0.25	0.45	-0.29	-0.41	-0.72	-0.86	0.44	-0.9	-0.85	0.45		0.84	-0.86	-0.84	-0.43
Roe	0.99	-0.99	0.97	-0.9	0.78	0.36	0.76	-0.26	-0.99	0.99	0.88	-0.28	0.62	-0.72	-0.01	-0.89	-0.99	0.7	-0.57	-1.0	0.8	0.84		-0.99	-0.99	-0.35
Ev To Operating Cash Flow	-1.0	1.0	-0.98	0.95	-0.69	-0.22	-0.69	0.4	1.0	-1.0	-0.82	0.42	-0.5	0.63	0.05	0.88	1.0	-0.58	0.63	0.99	-0.7	-0.86	-0.99		1.0	0.49
Pe Ratio	-1.0	1.0	-0.97	0.94	-0.71	-0.25	-0.71	0.39	1.0	-1.0	-0.83	0.41	-0.5	0.66	0.05	0.87	1.0	-0.6	0.6	0.99	-0.73	-0.84	-0.99	1.0		0.47
Return On Tangible Assets	-0.47	0.46	-0.42	0.68	0.19	0.64	0.11	0.99	0.46	-0.46	0.02	0.94	0.5	-0.21	0.32	0.31	0.49	0.42	0.55	0.37	0.18	-0.43	-0.35	0.49	0.47

Click cells to compare fundamentals

SAB Biotherapeutics Account Relationship Matchups

High Positive Relationship

Ev To Sales	+ 1.0	Price To Sales Ratio
Pb Ratio	+ 1.0	Ptb Ratio
Pocfratio	+ 1.0	Ptb Ratio
Ev To Operating Cash Flow	+ 1.0	Ptb Ratio
Pe Ratio	+ 1.0	Ptb Ratio
Pocfratio	+ 1.0	Pb Ratio

High Negative Relationship

Roe	- 1.0	Pfcf Ratio
Pe Ratio	- 1.0	Ev To Sales
Ev To Operating Cash Flow	- 1.0	Ev To Sales
Pfcf Ratio	- 1.0	Ev To Sales
Pocfratio	- 1.0	Ev To Sales
Ev To Sales	- 1.0	Pb Ratio

SAB Biotherapeutics fundamentals Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Price To Sales Ratio	4.67	3.51	1.07	16.97	19.51	18.54
Ptb Ratio	6.61	5.54	0.83	0.66	0.6	0.63
Book Value Per Share	15.36	14.1	7.14	10.38	9.34	7.5
Free Cash Flow Yield	(0.0106)	(0.0337)	(0.28)	(0.67)	(0.77)	(0.73)
Operating Cash Flow Per Share	3.94	1.37	0.86	(4.55)	(5.23)	(4.97)
Pb Ratio	6.61	5.54	0.83	0.66	0.6	0.63
Ev To Sales	4.58	3.07	0.69	(5.66)	(6.51)	(6.18)
Free Cash Flow Per Share	(1.07)	(2.63)	(1.65)	(4.59)	(5.27)	(5.01)
Roic	0.43	(0.24)	(0.76)	(0.51)	(0.58)	(0.61)
Net Income Per Share	7.92	(6.38)	(4.31)	(7.64)	(8.79)	(8.35)
Sales General And Administrative To Revenue	0.12	0.28	0.69	10.63	9.57	10.04
Research And Ddevelopement To Revenue	0.51	0.94	1.52	7.38	6.64	6.97
Cash Per Share	4.97	12.15	3.46	10.24	9.22	4.95
Pocfratio	25.76	56.81	6.83	(1.51)	(1.36)	(1.43)
Interest Coverage	43.82	(45.48)	(95.89)	(120.77)	(138.88)	(131.94)
Pfcf Ratio	(94.51)	(29.72)	(3.57)	(1.5)	(1.35)	(1.42)
Roe	0.52	(0.45)	(0.6)	(0.74)	(0.85)	(0.8)
Ev To Operating Cash Flow	25.31	49.77	4.41	0.5	0.45	0.48
Pe Ratio	12.81	(12.24)	(1.37)	(0.9)	(0.81)	(0.85)
Return On Tangible Assets	0.36	(0.22)	(0.37)	(0.5)	(0.58)	(0.55)
Ev To Free Cash Flow	(92.87)	(26.03)	(2.3)	0.5	0.45	0.47
Earnings Yield	0.0781	(0.0817)	(0.73)	(1.11)	(1.28)	(1.21)
Net Debt To E B I T D A	(0.21)	1.74	0.6	1.33	1.2	1.26
Current Ratio	3.11	1.96	1.47	5.45	4.9	5.15
Tangible Book Value Per Share	15.36	14.1	7.14	10.38	9.34	7.5
Graham Number	52.33	44.99	26.29	42.24	38.02	26.62
Shareholders Equity Per Share	15.36	14.1	7.14	10.38	9.34	7.5
Debt To Equity	0.21	0.17	0.19	0.1	0.0928	0.0974
Capex Per Share	5.01	4.0	2.51	0.0357	0.0411	0.039
Graham Net Net	4.14	(0.59)	(0.15)	5.42	4.88	5.12

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

BTC	Bitcoin
TRX	TRON
BNB	Binance Coin

Additional Tools for SAB Stock Analysis

When running SAB Biotherapeutics' price analysis, check to measure SAB Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SAB Biotherapeutics is operating at the current time. Most of SAB Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of SAB Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SAB Biotherapeutics' price. Additionally, you may evaluate how the addition of SAB Biotherapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Price To Sales Ratio	Dividend Yield
Ptb Ratio	Days Sales Outstanding
Book Value Per Share	Free Cash Flow Yield
Invested Capital	Operating Cash Flow Per Share
Average Payables	Stock Based Compensation To Revenue
Capex To Depreciation	Pb Ratio
Ev To Sales	Free Cash Flow Per Share
Roic	Inventory Turnover
Net Income Per Share	Days Of Inventory On Hand
Payables Turnover	Sales General And Administrative To Revenue
Average Inventory	Research And Ddevelopement To Revenue
Capex To Revenue	Cash Per Share
Pocfratio	Interest Coverage
Payout Ratio	Capex To Operating Cash Flow
Pfcf Ratio	Days Payables Outstanding
Net Current Asset Value	Income Quality
Roe	Tangible Asset Value
Ev To Operating Cash Flow	Pe Ratio
Return On Tangible Assets	Ev To Free Cash Flow
Earnings Yield	Intangibles To Total Assets
Net Debt To E B I T D A	Current Ratio
Tangible Book Value Per Share	Receivables Turnover
Graham Number	Shareholders Equity Per Share
Debt To Equity	Capex Per Share
Graham Net Net	Average Receivables
Revenue Per Share	Interest Debt Per Share
Debt To Assets	Enterprise Value Over E B I T D A
Short Term Coverage Ratios	Price Earnings Ratio
Operating Cycle	Price Book Value Ratio
Price Earnings To Growth Ratio	Days Of Payables Outstanding
Dividend Payout Ratio	Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio	Pretax Profit Margin
Ebt Per Ebit	Operating Profit Margin
Effective Tax Rate	Company Equity Multiplier
Long Term Debt To Capitalization	Total Debt To Capitalization
Return On Capital Employed	Debt Equity Ratio
Ebit Per Revenue	Quick Ratio
Dividend Paid And Capex Coverage Ratio	Net Income Per E B T
Cash Ratio	Cash Conversion Cycle
Operating Cash Flow Sales Ratio	Days Of Inventory Outstanding
Days Of Sales Outstanding	Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios	Price To Book Ratio
Fixed Asset Turnover	Capital Expenditure Coverage Ratio
Price Cash Flow Ratio	Enterprise Value Multiple
Debt Ratio	Cash Flow To Debt Ratio
Price Sales Ratio	Return On Assets
Asset Turnover	Net Profit Margin
Gross Profit Margin	Price Fair Value
Return On Equity

SAB Historical Financial Ratios

About SAB Financial Ratios Analysis

SAB Biotherapeutics Financial Ratios Chart

Price To Sales Ratio

Average Payables

Payables Turnover

SAB Biotherapeutics fundamentals Correlations

SAB Biotherapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

SAB Biotherapeutics fundamentals Accounts

Also Currently Popular

Additional Tools for SAB Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY